AVXL (Anavex Life Sciences) ROE % Adjusted to Book Value: -7.86% (As of Dec. 2025)


AVXL Anavex Life Sciences Corp AVXL
30 GF Score
Price $2.62
! 1 Warning Sign
View Full Analysis

What is Anavex Life Sciences ROE % Adjusted to Book Value?

Anavex Life Sciences AVXL +6.50% 30 ROE % Adjusted to Book Value is -7.86% as of Dec. 2025. GuruFocus rates AVXL with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Anavex Life Sciences's ROE % for the quarter that ended in Dec. 2025 was -20.52%. Anavex Life Sciences's PB Ratio for the quarter that ended in Dec. 2025 was 2.61. Anavex Life Sciences's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -7.86%.

Anavex Life Sciences ROE % Adjusted to Book Value Related Terms

Anavex Life Sciences ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Anavex Life Sciences's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anavex Life Sciences ROE % Adjusted to Book Value Chart

Anavex Life Sciences Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.72 -5.79 -8.82 -8.18 -5.30

Anavex Life Sciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.09 -5.79 -6.41 -5.20 -7.86

AVXL vs ZNTL, HUMA, SABS: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Anavex Life Sciences's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anavex Life Sciences ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Anavex Life Sciences's ROE % Adjusted to Book Value falls into.


AVXL
30GF Score
Anavex Life Sciences Corp AVXL
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anavex Life Sciences ROE % Adjusted to Book Value Calculation

Anavex Life Sciences's ROE % Adjusted to Book Value for the fiscal year that ended in Sep. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-43.11% / 8.13
=-5.30%

Anavex Life Sciences's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-20.52% / 2.61
=-7.86%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -7.86% mean?
Anavex Life Sciences (AVXL) has a ROE % Adjusted to Book Value of -7.86% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Anavex Life Sciences and its competitors.
Is Anavex Life Sciences' ROE % Adjusted to Book Value too high?
Anavex Life Sciences' current ROE % Adjusted to Book Value is -7.86%. Overall, Anavex Life Sciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Anavex Life Sciences' ROE % Adjusted to Book Value compare to ZNTL and HUMA?
Anavex Life Sciences' ROE % Adjusted to Book Value of -7.86% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Anavex Life Sciences and its competitors. Anavex Life Sciences's current ROE % Adjusted to Book Value is -7.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anavex Life Sciences stock overvalued right now?
Anavex Life Sciences (AVXL) has a current ROE % Adjusted to Book Value of -7.86%. The current ROE % Adjusted to Book Value is -7.86%. Anavex Life Sciences' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Anavex Life Sciences (AVXL), the current ROE % Adjusted to Book Value is -7.86% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anavex Life Sciences Business Description

Other Exchanges 0HFR:UK12X1:Germany
Address 630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
30GF Score

Get the complete analysis for AVXL

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.62
Price